Assesses mortality trends in invasive aspergillosis patients with hematologic malignancies, indicating a need for host enhancement alongside antifungal treatment.
Given competing death causalities among hematological malignancy patients with invasive aspergillosis (IA), we assessed IA-attributable, contributable, and all-cause mortalities in patients with culture-confirmed IA. Although attributable mortality decreased, contributable and all-cause mortalities remained high. Our data suggest that improving survival would require host augmentation, in addition to improved antifungals.
No takes yet. Share an insight, caveat, or question.
Szvalb et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: